Evergreen Private Wealth LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 17.5% in the 3rd quarter, HoldingsChannel reports. The firm owned 59,884 shares of the company’s stock after acquiring an additional 8,901 shares during the quarter. Zoetis makes up approximately 1.5% of Evergreen Private Wealth LLC’s holdings, making the stock its 29th largest holding. Evergreen Private Wealth LLC’s holdings in Zoetis were worth $4,182,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently made changes to their positions in ZTS. BlackRock Inc. boosted its holdings in Zoetis by 10.8% in the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares during the last quarter. State Street Corp grew its position in Zoetis by 1.8% during the 2nd quarter. State Street Corp now owns 19,667,723 shares of the company’s stock worth $1,413,323,000 after purchasing an additional 343,322 shares during the period. Deutsche Bank AG raised its stake in shares of Zoetis by 5.8% during the 2nd quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock valued at $420,506,000 after buying an additional 319,709 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Zoetis by 7.3% during the 1st quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock valued at $571,150,000 after buying an additional 327,313 shares during the last quarter. Finally, Van ECK Associates Corp raised its stake in shares of Zoetis by 7.7% during the 2nd quarter. Van ECK Associates Corp now owns 4,252,140 shares of the company’s stock valued at $305,559,000 after buying an additional 303,395 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms recently commented on ZTS. BNP Paribas Exane dropped their target price on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, August 11th. Citigroup decreased their price target on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Jefferies Financial Group lowered Zoetis from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $103.00 to $83.00 in a research report on Tuesday, October 20th. Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a research note on Tuesday, August 25th. Finally, Stifel Nicolaus cut their target price on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a report on Thursday, August 20th. Six equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $93.79.
Get Our Latest Analysis on ZTS
Zoetis Trading Up 0.0%
Shares of ZTS stock opened at $83.19 on Wednesday. Zoetis Inc. has a 1-year low of $68.77 and a 1-year high of $132.49. The company has a market cap of $34.38 billion, a price-to-earnings ratio of 13.71, a PEG ratio of 1.23 and a beta of 0.67. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The stock has a 50 day simple moving average of $75.27 and a 200-day simple moving average of $93.22.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter last year, the company earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.15 EPS for the current fiscal year.
Zoetis Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s dividend payout ratio (DPR) is presently 34.93%.
About Zoetis
Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.
The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.
Featured Articles
- Five stocks we like better than Zoetis
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
